Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(N Engl J Med [JO] AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
190 results
  • A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. [Journal Article]
    N Engl J Med. 2020 Jun 03 [Online ahead of print]Boulware DR, Pullen MF, … Hullsiek KH
  • CONCLUSIONS: After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).
  • Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. [Journal Article]
    N Engl J Med. 2020 May 27 [Online ahead of print]Goldman JD, Lye DCB, … GS-US-540-5773 Investigators
  • CONCLUSIONS: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).
  • Hospitalization and Mortality among Black Patients and White Patients with Covid-19. [Journal Article]
    N Engl J Med. 2020 May 27 [Online ahead of print]Price-Haywood EG, Burton J, … Seoane L
  • CONCLUSIONS: In a large cohort in Louisiana, 76.9% of the patients who were hospitalized with Covid-19 and 70.6% of those who died were black, whereas blacks comprise only 31% of the Ochsner Health population. Black race was not associated with higher in-hospital mortality than white race, after adjustment for differences in sociodemographic and clinical characteristics on admission.
  • Remdesivir for the Treatment of Covid-19 - Preliminary Report. [Journal Article]
    N Engl J Med. 2020 May 22 [Online ahead of print]Beigel JH, Tomashek KM, … ACTT-1 Study Group Members
  • CONCLUSIONS: Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.).
  • Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. [Journal Article]
    N Engl J Med. 2020 May 21 [Online ahead of print]Ackermann M, Verleden SE, … Jonigk D
  • CONCLUSIONS: In our small series, vascular angiogenesis distinguished the pulmonary pathobiology of Covid-19 from that of equally severe influenza virus infection. The universality and clinical implications of our observations require further research to define. (Funded by the National Institutes of Health and others.).
New Search Next